News for October 2016

News Archive

Blood test for early osteoarthritis diagnosis unveiled Blood test for early osteoarthritis diagnosis unveiled

Patients could soon be diagnosed with early-stage arthritis several years before the onset of physical and irreversible symptoms, thanks to a new test developed by researchers at the University of Warwick.

TB Alliance Partners With PepsiCo To Advance The Fight For Improved Tuberculosis Medicines

Leveraging shared expertise to help eliminate unpleasant taste of TB medicines to improve palatability and treatment for children with TB

Catalent Celebrates Ground Breaking For Expanded Biologics Facility Catalent Celebrates Ground Breaking For Expanded Biologics Facility

Company to Invest $34M in Facility Extension to Add a New 2 x 2,000 Liter Single-Use Bioreactor System and Laboratory Space

Getting patients quicker access to innovative healthcare Getting patients quicker access to innovative healthcare

The Accelerated Access Review: final report, commissioned by the government and led by an independent chair, was published on 24th October. The review aims to make the UK a world-leader in healthcare innovation, with an NHS that embraces the new drugs and technologies that patients need and supports work with local areas to develop solutions to their specific healthcare needs.

Oxford BioDynamics presents results of study into epigenetic biomarkers for ALS at The Lancet Neurology Conference Oxford BioDynamics presents results of study into epigenetic biomarkers for ALS at The Lancet Neurology Conference

25th October 2016 – Oxford BioDynamics, an Oxford UK-based biotechnology firm, presented at The Lancet Neurology Conference at the Park Plaza Riverbank in London on 20th October 2016. The aim of the conference was to broadcast cutting-edge findings on preclinical neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

Cytomegalovirus Infection Relies on Human RNA-Binding Protein Cytomegalovirus Infection Relies on Human RNA-Binding Protein

New understanding of how cytomegalovirus interacts with host cells provides potential therapeutic target

ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER ACHILLES THERAPEUTICS LAUNCHED WITH FUNDS OF £13.2 MILLION TO DEVELOP IMMUNOTHERAPIES FOR CANCER

SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT) announce the formation of Achilles Therapeutics Ltd today The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR).

The RSC Returns to Lab Innovations 2016 to Cover Critical Industry Topics The RSC Returns to Lab Innovations 2016 to Cover Critical Industry Topics

The Royal Society of Chemistry (RSC) is returning to Lab Innovations 2016, the UK’s only event dedicated to laboratory professionals, to host a two-day conference in its own dedicated theatre. The hotly anticipated conference programme, taking place at the NEC Birmingham on 2 & 3 November, will feature leading speakers from the laboratory industry who will take to the stage to discuss a series of key topics, including digital healthcare and elemental discovery.

Blocking Ran protein reverses resistance of lung and breast cancers Blocking Ran protein reverses resistance of lung and breast cancers

Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein found in cancer cells.Suppressing this protein, called Ran-GTP, also causes cancer cells already resistant to the first-line chemotherapy treatment, gefitinib, to become re-sensitised to the drug.